DUX4 and facioscapulohumeral muscular dystrophy: The remaining 5% of FSHD cases are classified as FSHD type 2, and studies have shown that pathogenic variants in epigenetic modifiers such as SMCHD1, DNMT3B, and LRIF1 result in hypomethylation, allowing DUX4 expression.